文献速递肾癌与肾肿瘤

舒尼替尼治疗后行减瘤性肾切除术的手术安全性:立即与延迟肾切除术多中心随机对照试验(SURTIME)结果

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
PubMed 文献 · Eur Urol · 2019-06-18

SURTIME试验比较转移性肾细胞癌患者立即减瘤性肾切除术(CN)后舒尼替尼与舒尼替尼后延迟CN(末次给药后24小时)的手术安全性。延迟组无肿瘤变为不可切除,仅2例因舒尼替尼相关原因CN延迟超过2周。两组手术相关不良事件发生率分别为52%和53%,术后CD≥3级不良事件、30天再入院和院内死亡率在立即组分别为6.5%、13%、4.3%,延迟组分别为2.5%、7.5%、2.5%。

要点

  • 延迟组无肿瘤变为不可切除,仅2例CN因舒尼替尼相关原因延迟超过2周。
  • 手术相关不良事件(所有级别)立即组52% vs 延迟组53%,术中手术相关不良事件立即组更多。
  • 术后CD≥3级不良事件立即组6.5% vs 延迟组2.5%,30天再入院立即组13% vs 延迟组7.5%,院内死亡立即组4.3% vs 延迟组2.5%。

核心结论

  • 转移性肾癌患者无论先接受全身治疗再手术还是先手术再全身治疗,手术并发症无差异。

研究设计与样本

  • 欧洲癌症研究与治疗组织SURTIME试验,多中心随机对照试验,1:1随机分配至立即CN后舒尼替尼组与舒尼替尼后延迟CN组(末次舒尼替尼给药后24小时行CN)。

主要发现

  • 延迟组无肿瘤变为不可切除,仅2例患者CN因舒尼替尼相关原因延迟超过2周。
  • 手术相关不良事件(所有级别)立即组52% vs 延迟组53%,术中手术相关不良事件立即组更多。
  • 术后CD≥3级不良事件立即组6.5% vs 延迟组2.5%,30天再入院立即组13% vs 延迟组7.5%,院内死亡立即组4.3% vs 延迟组2.5%。
  • 手术时间、出血量和住院时间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European Organisation for Research and Treatment of Cancer SURTIME trial explored timing of sunitinib, a tyrosine kinase inhibitor (TKI), and cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. Previous retrospective studies suggest increased surgery-related adverse events (AEs) after presurgical TKI. We report surgical safety from a randomised comparison of CN before or after sunitinib. In-hospital mortality, 30-d readmission rate, and intraoperative and 30-d postoperative AEs according to Common Terminology Criteria for Adverse Events version 4 and Clavien-Dindo (CD) were analysed. Patients were randomised 1:1 to immediate CN followed by sunitinib versus sunitinib followed by deferred CN 24h after the last dose of sunitinib. None of the tumours in the deferred arm became unresectable, and only two patients had a sunitinib-related delay of CN of >2wk. AEs related to surgery (all grades) in the immediate and deferred arms occurred in 52% and 53% after CN, respectively, although the number of intraoperative surgery-related AEs was higher in the immediate arm. Postoperative AEs (CD ≥3), 30-d readmission, and in-hospital mortality rates were 6.5%, 13%, and 4.3% in the immediate arm and 2.5%, 7.5%, and 2.5% in the deferred arm, respectively. There were no differences in surgery time, blood loss, and hospital stay. PATIENT SUMMARY: Patients with metastatic kidney cancer do not have more surgical complications irrespective of whether they are treated with systemic therapy before or after surgery.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. De Bruijn RE, Mulders P, Jewett MA, et al. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). Eur Urol. 2019. PMID: 31227307. doi:10.1016/j.eururo.2019.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。